Compare Stocks: KRRO, CTMX, NVCT, and MNPR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$3.35 -5.4%	$3.48	$1.90 ▼ $8.21	$771.36M	2.14	2.95 million shs	2.06 million shs
KRRO Korro Bio	$13.06 +1.0%	$12.62	$5.20 ▼ $55.89	$190.40M	3.09	75,399 shs	145,793 shs
MNPR Monopar Therapeutics	$109.96 -2.2%	$111.26	$42.51 ▼ $124.82	$754.31M	1.49	161,731 shs	89,538 shs
NVCT Nuvectis Pharma	$22.49 -1.3%	$20.99	$5.55 ▼ $29.27	$743.63M	-0.26	190,110 shs	107,047 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	-5.37%	-8.97%	-2.90%	+11.30%	+61.84%
KRRO Korro Bio	+1.01%	+12.39%	-1.95%	+12.49%	-63.22%
MNPR Monopar Therapeutics	-2.15%	-7.25%	-3.93%	+83.97%	+156.32%
NVCT Nuvectis Pharma	-1.27%	-7.71%	+15.87%	+109.99%	+258.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$3.35 -5.4%	$3.48	$1.90 ▼ $8.21	$771.36M	2.14	2.95 million shs	2.06 million shs
KRRO Korro Bio	$13.06 +1.0%	$12.62	$5.20 ▼ $55.89	$190.40M	3.09	75,399 shs	145,793 shs
MNPR Monopar Therapeutics	$109.96 -2.2%	$111.26	$42.51 ▼ $124.82	$754.31M	1.49	161,731 shs	89,538 shs
NVCT Nuvectis Pharma	$22.49 -1.3%	$20.99	$5.55 ▼ $29.27	$743.63M	-0.26	190,110 shs	107,047 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	-5.37%	-8.97%	-2.90%	+11.30%	+61.84%
KRRO Korro Bio	+1.01%	+12.39%	-1.95%	+12.49%	-63.22%
MNPR Monopar Therapeutics	-2.15%	-7.25%	-3.93%	+83.97%	+156.32%
NVCT Nuvectis Pharma	-1.27%	-7.71%	+15.87%	+109.99%	+258.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	255.22% Upside
KRRO Korro Bio	2.92	Moderate Buy	$16.71	27.98% Upside
MNPR Monopar Therapeutics	2.86	Moderate Buy	$118.67	7.92% Upside
NVCT Nuvectis Pharma	2.80	Moderate Buy	$36.25	61.18% Upside

Current Analyst Ratings Breakdown

Latest KRRO, CTMX, NVCT, and MNPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/1/2026	NVCT Nuvectis Pharma	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$40.00
9/1/2026	NVCT Nuvectis Pharma	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	NVCT Nuvectis Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
8/20/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
8/19/2026	CTMX CytomX Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	MNPR Monopar Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$130.00
8/13/2026	MNPR Monopar Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$125.00 ➝ $128.00
8/13/2026	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$109.00 ➝ $119.00
8/13/2026	CTMX CytomX Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $11.00

(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$76.20M	9.58	N/A	N/A	$0.58 per share	5.78
KRRO Korro Bio	$6.39M	30.11	N/A	N/A	$5.46 per share	2.39
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$20.62 per share	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.72 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
KRRO Korro Bio	-$117.26M	-$10.00	N/A	N/A	N/A	-1,834.48%	-114.26%	-68.57%	11/11/2026 (Estimated)
MNPR Monopar Therapeutics	-$13.72M	-$2.17	N/A	N/A	N/A	N/A	-13.08%	-12.79%	11/12/2026 (Estimated)
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	11/3/2026 (Estimated)

Latest KRRO, CTMX, NVCT, and MNPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	MNPR Monopar Therapeutics	-$0.6425	-$0.62	+$0.0225	-$0.7920	N/A	N/A
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million
8/6/2026	Q2 2026	KRRO Korro Bio	-$1.34	-$1.07	+$0.27	-$1.07	$0.21 million	N/A
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	9.36	9.36
KRRO Korro Bio	N/A	9.55	9.55
MNPR Monopar Therapeutics	N/A	33.56	33.56
NVCT Nuvectis Pharma	N/A	1.68	1.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
KRRO Korro Bio	13.18%
MNPR Monopar Therapeutics	1.83%
NVCT Nuvectis Pharma	96.77%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	3.80%
KRRO Korro Bio	4.80%
MNPR Monopar Therapeutics	9.70%
NVCT Nuvectis Pharma	28.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	217.90 million	209.62 million	Optionable
KRRO Korro Bio	70	14.73 million	14.02 million	No Data
MNPR Monopar Therapeutics	10	6.71 million	6.06 million	Not Optionable
NVCT Nuvectis Pharma	8	32.64 million	23.32 million	Not Optionable

KRRO, CTMX, NVCT, and MNPR Headlines

Recent News About These Companies

Nuvectis Pharma, Inc. (NASDAQ:NVCT) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 9 at 3:28 AM | americanbankingnews.com

Nuvectis Pharma, Inc. (NASDAQ:NVCT) Given Consensus Recommendation of "Moderate Buy" by Analysts

September 4, 2026 | marketbeat.com

Nuvectis Pharma (NASDAQ:NVCT) Upgraded by Lucid Cap Mkts to "Strong-Buy" Rating

September 4, 2026 | marketbeat.com

BlackRock Inc. Acquires New Stake in Nuvectis Pharma, Inc. $NVCT

September 4, 2026 | marketbeat.com

Some of the Top Biotech Funds Just Bought Into This Under-the-Radar Biotech (NASDAQ: NVCT)

September 3, 2026 | markets.businessinsider.com

Nuvectis Pharma To Participate in Upcoming Investor Conferences

September 3, 2026 | globenewswire.com

Alyeska Investment Group L.P. Purchases New Shares in Nuvectis Pharma, Inc. $NVCT

September 2, 2026 | marketbeat.com

Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 4.2% - Here's Why

September 1, 2026 | marketbeat.com

Stonepine Capital Management LLC Makes New Investment in Nuvectis Pharma, Inc. $NVCT

August 28, 2026 | marketbeat.com

Nuvectis Pharma (NASDAQ:NVCT) Shares Down 5.2% - Here's What Happened

August 26, 2026 | marketbeat.com

Cantor Fitzgerald Initiates Coverage on Nuvectis Pharma (NASDAQ:NVCT)

August 24, 2026 | marketbeat.com

Nuvectis Stock Surges Around 97% in 3 Months: Here's Why

August 19, 2026 | zacks.com

Nuvectis Pharma (NASDAQ:NVCT) Trading 6.2% Higher - What's Next?

August 18, 2026 | marketbeat.com

Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up - What's Next?

August 14, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and EyePoint Pharmaceuticals (EYPT)

August 9, 2026 | theglobeandmail.com

Nuvectis’ NXP800 Ovarian Cancer Trial Terminated: What Investors Should Watch Next

August 6, 2026 | tipranks.com

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

August 4, 2026 | finance.yahoo.com

Nuvectis Pharma Reports Q2 2026 Results, Highlights In-Licensing of Ciprocopan and NXP200 and $115 Million Follow-On Offering

August 4, 2026 | quiverquant.comQ

Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know

July 29, 2026 | zacks.com

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement ...

July 23, 2026 | markets.businessinsider.com

Nuvectis' NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor

July 23, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO, CTMX, NVCT, and MNPR Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$3.35 -0.19 (-5.37%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$3.40 +0.05 (+1.64%)

As of 04:37 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Korro Bio NASDAQ:KRRO

$13.06 +0.13 (+1.01%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$13.09 +0.03 (+0.23%)

As of 09/10/2026 07:30 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Monopar Therapeutics NASDAQ:MNPR

$109.96 -2.42 (-2.15%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$110.86 +0.91 (+0.82%)

As of 09/10/2026 07:57 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Nuvectis Pharma NASDAQ:NVCT

$22.49 -0.29 (-1.27%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$22.53 +0.04 (+0.18%)

As of 09/10/2026 07:30 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KRRO, CTMX, NVCT, and MNPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KRRO, CTMX, NVCT, and MNPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KRRO, CTMX, NVCT, and MNPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO, CTMX, NVCT, and MNPR Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Korro Bio NASDAQ:KRRO

Monopar Therapeutics NASDAQ:MNPR

Nuvectis Pharma NASDAQ:NVCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KRRO, CTMX, NVCT, and MNPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KRRO, CTMX, NVCT, and MNPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KRRO, CTMX, NVCT, and MNPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO, CTMX, NVCT, and MNPR Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Korro Bio NASDAQ:KRRO

Monopar Therapeutics NASDAQ:MNPR

Nuvectis Pharma NASDAQ:NVCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools